An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

NCT01833039 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Relapsed or Refractory Mantle Cell Lymphoma

Interventions

DRUG: Ibrutinib

Sponsor

Janssen Biotech, Inc.

Collaborators

[object Object]